SanBio Company Limited (4592.T)
Tokyo · JPY · Healthcare · Biotechnology
¥930 (+3.33%) as of
Key statistics
- Market cap
- 72.59B
- Forward P/E
- -22.79
- EPS (TTM)
- -47.70
- Dividend yield
- 0.00%
- 52-week range
- 858.00 – 2,933.00
- Beta
- 0.29
- Profit margin
- 0.00%
- Analyst target
- ¥1,400
- Volume
- 579.70k
About SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tokyo, Japan
- Employees
- 33
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.